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Cellular proteins have been implicated as important for HIV-1
reverse transcription, but whether any are reverse transcription
complex (RTC) cofactors or affect reverse transcription indirectly is
unclear. Here we used protein fractionation combined with an
endogenous reverse transcription assay to identify cellular pro-
teins that stimulated late steps of reverse transcription in vitro. We
identiﬁed 25 cellular proteins in an active protein fraction, and
here we show that the eEF1A and eEF1G subunits of eukaryotic
elongation factor 1 (eEF1) are important components of the HIV-1
RTC. eEF1A and eEF1G were identiﬁed in fractionated human T-cell
lysates as reverse transcription cofactors, as their removal ablated
the ability of active protein fractions to stimulate late reverse
transcription in vitro. We observed that the p51 subunit of reverse
transcriptase and integrase, two subunits of the RTC, coimmuno-
precipitated with eEF1A and eEF1G. Moreover eEF1A and eEF1G
associated with puriﬁed RTCs and colocalized with reverse tran-
scriptase following infection of cells. Reverse transcription in cells
was sharply down-regulated when eEF1A or eEF1G levels were
reduced by siRNA treatment as a result of reduced levels of RTCs
in treated cells. The combined evidence indicates that these eEF1
subunits are critical RTC stability cofactors required for efﬁcient
completion of reverse transcription. The identiﬁcation of eEF1 sub-
units as unique RTC components provides a basis for further inves-
tigations of reverse transcription and trafﬁcking of the RTC to
the nucleus.
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The HIV type-1 (HIV-1) reverse transcriptase (RT) enzymecarries out reverse transcription through DNA polymerase
and RNase H activities, which mediate a sequential series of steps
that include the initiation of DNA synthesis producing negative
strand strong stop DNA (−ssDNA), full-length negative-strand
DNA, positive-strand DNA, and intact preintegrative double-
strand DNA (reviewed elsewhere 1). The ability of HIV-1 to ef-
ﬁciently produce early reverse transcription products in vitro has
been described (2). However, under in vitro conditions, the pro-
duction of late reverse transcription products is less efﬁcient than
that observed in HIV-1–infected cells (3, 4), suggesting that host
cellular factors are required. After entry into the host cell cyto-
plasm, the HIV-1 core, containing the viral genomic RNA, RT,
and integrase (IN), reorganizes to form the reverse transcription
complex (RTC). The RTC requires both IN and RT to be active
(5), and they are believed to recruit cellular factors to facilitate
DNA synthesis (6). Although two-hybrid library and genome-
wide RNAi screening methods have implicated more than 50
cellular proteins as important for reverse transcription (6, 7),
whether any of these cellular proteins are RTC components, or
whether they direct the RTC in other ways, is unclear.
Attempts to purify and to identify cellular RTC cofactors by
more conventional methods have only partly succeeded (4, 8).
Narayan et al. showed that in vitro fusion of avian sarcoma and
leukosis virus endosomal particles required the addition of cel-
lular lysates for formation of productive RTCs, which greatly
increased early and late products of reverse transcription (8).
They reported that the reverse transcription enhancing activity
was >5 kDa in mass and required ATP hydrolysis. Warrilow et al.
showed that cell lysate made from human and murine cell lines
contained an activity that did not affect synthesis of -ssDNA but
did improve late DNA synthesis by up to 30-fold (4, 9). The
stimulatory activity, isolated by size-exclusion chromatography,
puriﬁed with an apparent molecular mass of >20 MDa, sug-
gesting that it was associated with a complex of molecules such
as aggregated protein, DNA, or RNA. This study aimed to
identify cellular factors that stimulate reverse transcription by
chromatographic methods.
Here we show that subunits of the eukaryotic elongation fac-
tor 1 (eEF1) complex are required to stimulate late stages of
HIV-1 reverse transcription in vitro, as depletion of eEF1 sub-
units eEF1A and eEF1G ablated the ability of active protein
fractions to stimulate late steps of HIV-1 reverse transcription.
These eEF1 subunits coimmunoprecipitate RTC proteins in
vitro, and following cell infection cosediment with RTCs by iso-
pycnography and colocalize with RT as shown by proximity
ligation assay. We also observed signiﬁcant down-regulation of
reverse transcription efﬁciency when eEF1A and eEF1G protein
levels were reduced by siRNA treatment that was attributed to
reduced levels of RTC in infected cells. Further investigation of
the eEF1 and RTC interaction has implications with respect to
trafﬁcking and nuclear import of HIV reverse transcription/pre-
integration complexes (PICs).
Results
Puriﬁcation and Identiﬁcation of Cellular Proteins in Fractions That
Stimulate Reverse Transcription in Vitro. We previously conﬁrmed
an activity in a partially puriﬁed cytoplasmic lysate derived from
a human T cell line (Jurkat), named S100, that increased the
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ability of HIV-1 to generate late endogenous reverse transcrip-
tion (ERT) products in vitro (4, 9) in a concentration-dependent
manner (Fig. S1A). We deﬁned reverse transcription efﬁciency as
the ability to synthesize late HIV-1 DNA relative to early DNA
product expressed as a percentage. Starting with S100, the activity
was fractionated through a CL-4B Sepharose column, where the
stimulatory activity, referred to as the “peak of gel ﬁltration”
(PGF), was detected only in fractions with a high molecular mass
(9). Next, 1 mg PGF protein was applied to a DEAE anion-ex-
change column that resulted in isolation of reverse transcription
stimulatory activity in very few fractions (Fig. 1), and will be
hereafter referred to as “DEAE active fraction” (DAF). SDS/
PAGE analysis of DAF revealed well-deﬁned, Coomassie-stained
protein bands (Fig. S1B) that were excised, digested with trypsin,
and subjected to liquid chromatography–mass spectrometry (LC-
MS/MS) analysis. The protein puriﬁcation and MS-identiﬁcation
process was repeated four times, and 25 host proteins were iden-
tiﬁed in at least three of the four experiments (Table S1).
The identiﬁed proteins fall into six broad function classes:
translation factors, transcription regulators, synthetases, mRNA
splicing/transport factors, folding/transport proteins, and cellular
organization cytoskeleton proteins. Of particular interest was the
identiﬁcation of translation factors, which are essential not only
for translation but for a range of functions throughout eukaryotic
cells. Two subunits of the eEF1 complex were detected, eEF1A
and eEF1G, in addition to eukaryotic translation elongation
factor 2 (eEF2) and the α-subunit of the eukaryotic translation
initiation factor 3 (eIF3A). The nonribosomal eEF1 protein
complex composed of eEF1A, eEF1G, eEF1B2 (also called,
eEF1Bα), eEF1D (also called eEF1δ or eEF1Bβ), and valyl-
tRNA synthetase is required for eukaryotic translation (10) (Fig.
S2A). However, eEF1A has many noncanonical roles in the cell
(11) and in virus replication (12–15). In addition, eEF1A was
reported to interact with HIV-1 Gag (16) and the cytoskeletal
networks (17) that are thought to play crucial role in the com-
pletion of HIV-1 reverse transcription (18). Western blot anal-
ysis performed using DAF conﬁrmed that eEF1D and eEF1B2
were also present (Fig. S2B). Moreover, the immunodepletion of
eEF1G codepleted other eEF1 complex protein members (Fig.
S2C). This indicated that eEF1A, eEF1B2, eEF1D, and eEF1G
exist as a complex in DAF.
DAF Reverse Transcription Stimulatory Activity Is Down-Regulated by
Immunodepletion of eEF1A and eEF1G. Larger-scale DAF puriﬁ-
cation was undertaken to obtain larger quantities of protein.
Western blot and ERT analysis of DEAE fractions indicated that
a peak level of eEF1A and eEF1G in fractions was coincident to
a peak of ERT stimulatory activity, although they were present at
reduced levels in subsequent fraction (Fig. S3). To determine
whether eEF1A or eEF1G were required for stimulatory activity,
DAF was incubated with agarose beads covalently coupled to
anti–(α)-eEF1A, α-eEF1G, or α-eIF3A antibodies to reduce
their concentration in the unbound fraction. DAF was incubated
with BSA protein–coupled beads as a control. Western blot
analysis of treated DAF showed that the levels of the respective
proteins were reduced by ∼90%, 70%, and 95%, respectively
(Fig. 2A). The activity of the depleted DAFs was tested using
in vitro ERT reactions in parallel with control reactions con-
taining intact DAF or no added protein (i.e., buffer only). Fig. 2B
shows that depletion of eEF1A and eEF1G, but not eIF3A,
resulted in sharply reduced reverse transcription efﬁciency in
ERT. In all experiments (n = 4), a complete loss of reverse
transcription stimulatory activity was observed when eEF1G
levels were reduced by 70–90%, whereas it was reduced by three-
to fourfold when eEF1A was depleted by 90–95% (Fig. 2B).
eEF2 was refractory to immunodepletion with the available
antibodies. An increase in reverse transcription efﬁciency ob-
served in these reactions compared with Fig. 1 was consistent
with increased quantity of cellular cofactors used in the reactions
that increased reverse transcription efﬁciency in a titratable
manner (Fig. S1A). Of note, we previously reported separation
of ERT-stimulatory activities into S100 (soluble) and P100
(pellet) fractions that had additive effects, most likely because
eEF1A and eEF1G were in both fractions (4) (Fig. S4). We
conclude that eEF1A and eEF1G translation factors found in
DAF, perhaps as part of an active eEF1 complex (Fig. S2), were
required to stimulate late HIV-1 reverse transcription in vitro.
Both eEF1A and eEF1G Coimmunoprecipitate RT and IN. The obser-
vation that eEF1A or eEF1G were required to stimulate reverse
transcription suggested they interacted with the HIV-1 RTC. To
address this possibility, large-scale ERT reactions containing
DAF were immunoprecipitated using α-eEF1A– or α-eEF1G–
coated beads. SDS/PAGE and Western blot analysis of the
coprecipitated protein using an α–HIV-1 polyclonal antibody
revealed two HIV-1 proteins with apparent masses of 51 and 31
kDa (Fig. 3A, Left), most likely the p51 subunit of RT and IN,
respectively. HIV-1 proteins were not speciﬁcally coimmuno-
precipitated by α-eIF3A–coated beads (Fig. 3A, Right). Whereas
the RT p51 subunit was consistently coimmunoprecipitated with
α-eEF1G and α-eEF1A antibodies, IN was detected inconsis-
tently, possibly because the avidity or titer of the α-IN antibody
component in the anti–HIV-1 polyclonal antibody was low. The
coimmunoprecipitation experiments and Western blots were
repeated using high-avidity α–HIV-1-RT and α–HIV-1-IN
monoclonal antibodies separately. As shown, HIV-1 RT and IN
were consistently coimmunoprecipitated with eEF1A or eEF1G,
verifying that these cellular proteins associated with enzymatic
components of the RTC (Fig. 3B), and supporting the hypothesis
that a stimulatory activity in DAF was mediated by subunits of
the eEF1 complex through an interaction with the viral RTC.
eEF1A and eEF1G Subunits of eEF1 Associate with RTCs in Infected
Cells. To test the hypothesis that the eEF1 complex asso-
ciated with RTC in cells, HEK293T cells were infected with
HIV-1pNL4-3.Luc.R-E- pseudotyped with VSV-G or with heat-
inactivated virus stock. HIV-1 was incubated with HEK293T
target cells at 4 °C for 2 h to allow virus attachment to cells,
then at 37 °C for a 4-h infection. Cell lysates were made from
the infected and control cells and were fractionated by iso-
pycnography. Fractions collected from the bottom of the gradi-
ent were assayed for viral DNA by quantitative PCR and RT,
eEF1A and eEF1G by Western blot. The analysis shows the
bottom eight fractions that include the sucrose densities of 1.32–
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Fig. 1. Puriﬁcation of cellular factors that enhance late HIV-1 reverse
transcription in vitro. PGF was further fractionated using a 1-mL DEAE col-
umn that resolved a fraction called DAF that was identiﬁed using an ERT
assay. A representative puriﬁcation and mass spectrometry analysis of four
experiments is shown (Fig. S1B and Table S1).
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1.34 g/mL reported to contain viral RTCs (19) (Fig. 4, dotted
box) that corresponded to fractions 3 and 4. Viral DNA was
observed with a peak level in fraction 3 (Fig. 4A) in agreement
with previous studies (19), whereas very little viral DNA was
detected in fractions from the control infection. As previously
described (19), fraction 3 also contained a signiﬁcant amount
of RT indicative of RTCs (Fig. 4B and Fig. S5A). The same
Western blot was stripped and probed with a mouse α-eEF1G
monoclonal antibody. The process was repeated using a rabbit
α-eEF1A polyclonal antibody. As shown in Fig. 4 and Fig. S5, the
level of eEF1G (Fig. 4C and Fig. S5B) and eEF1A (Fig. 4D and
Fig. S5C) was dramatically higher in fractions 3 and 4 compared
with the same fractions in the control experiment with the heat-
inactivated virus. This outcome supports the hypothesis that the
eEF1 complex speciﬁcally associates with viral RTC in cells, most
likely by interacting with the RT p51 subunit and IN (Fig. 3).
To further test the hypothesis that eEF1 complex subunits
associated with viral RTCs in infected cells, HeLa cells were
infected with VSV-G pseudotyped HIV-1pNL4-3.Luc.R-E-. Duolink
proximity ligation assays (PLA) (Fig. S6 A–G), a modiﬁed ﬂuo-
rescent in situ hybridization method, were performed to de-
termine whether HIV-1 RT was closely associated with either
translation elongation factor in infected cells. A mouse mono-
clonal antibody to RT was used in conjunction with rabbit
antibodies to eEF1A, eEF1G, or eIF3A individually to stain
uninfected or HIV-1–infected cells, and was subsequently pro-
cessed with oligonucleotide-conjugated detection antibodies,
a hybridization linker, and “red” oligonucleotide detector probe.
Maximum intensity projections of deconvolved images clearly
showed that RT was proximal to eEF1A and eEF1G, but not
eIF3A, in infected cells (Fig. 5 and Fig. S6F). We noted in
pairwise PLA assays performed with infected HeLa cells that the
number of red foci generated using α-RT antibody with α-eEF1A
or α-eEF1G antibody were very similar (Fig. 5 and Fig. S6F).
Importantly, very low numbers of foci were detected using the
same antibodies in uninfected cells (Fig. 5 and Fig. S6G). Given
a similar cellular distribution and high abundance of the trans-
lation factors generally (Fig. S6H), it is extremely likely that
proximity signals are highly signiﬁcant (Fig. 5; P = 7.2E-23 and
6.5E-28), favoring the possibility that the eEF1 complex, rather
than individual eEF1 subunits, interacted with RT. However, we
cannot exclude the possibility that RT or the RTC could bind to
eEF1A and to eEF1G individually.
siRNA Down-Regulation of eEF1A and eEF1G in Cells Negatively
Affects HIV-1 Reverse Transcription. Finally, cells were indepen-
dently treated with siRNAs targeting eEF1A or eEF1G, or a
control siRNA. In two separate experiments, eEF1A and eEF1G
levels were down-regulated by >90% compared with the control
(Fig. 6A), without affecting cell viability as determined by MTS
assays (Fig. S7). Treated or control HEK293T cells were infected
with VSV-G pseudotyped HIV-1pNL4-3.Luc.R-E- or heat-inacti-
vated virus at 4 °C for 2 h and then at 37 °C for 4 h, after which
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Fig. 2. Immunodepletion of eEF1A and eEF1G from active fractions decreases reverse transcription efﬁciency in vitro. DEAE active fraction (DAF) was in-
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the levels of reverse transcription DNA products in total cellular
DNA were measured by quantitative PCR, and the relative ef-
ﬁciency of reverse transcription was calculated. Down-regulation
of eEF1A or eEF1G had strong negative effects on reverse
transcription efﬁciency (Fig. 6B, bars), and a modest, ∼50%
decrease in the synthesis of (−) strong stop DNA in cells (Fig.
6B, markers) compared with control infections. AZT-treated
cells infected in parallel or cells infected with heat-inactivated
virus had very low levels of HIV-1 DNA, indicating that the viral
DNA synthesis was de novo (Fig. 6B). Interestingly, reverse
transcription by Moloney murine leukemia virus–like particles
was not affected signiﬁcantly in siRNA-treated cells compared
with control cells, but was inhibited by AZT treatment (Fig.
S8A). Finally, analysis of RTC isolated from control and siRNA-
treated cells by isopycnography, as previously described (Fig. 4),
showed a four- to ﬁvefold reduction in the level of RT in frac-
tions 3 and 4, to which RTCs sediment, when eEF1A or eEF1G
were down-regulated (Fig. 6 and Fig. S8B). Early DNA levels
were also decreased by about twofold (Fig. 6B). These outcomes
support the hypothesis that at least two members of the eEF1
complex, which includes eEF1A and eEF1G, associate with and
may improve the stability of the HIV-1 RTC, thereby increasing
the efﬁciency of reverse transcription.
Discussion
This report demonstrates a functional role for multiple subunits
of the eEF1 complex in HIV-1 early replication by supporting
efﬁcient reverse transcription. Given their relative abundance in
cells, eEF1 complex subunits are an obvious target for viral
subversion. The evidence herein strongly supports the hypothesis
that eEF1A and eEF1G associate with the HIV-1 RTC by in-
teraction with RT and/or IN and increase the stability of RTC in
the cellular cytoplasm. As IN is also an RT binding protein, the
precise contacts between eEF1 subunits and RTC components
requires further analysis. It is worth noting that eEF1A was
shown to interact with HIV-1 IN in vitro (20, 21), which may be
relevant to coimmunoprecipitations of IN with eEF1A or eEF1G
observed in this study. Given a tight association between RT and
IN (22), it is possible that an IN and eEF1A interaction resulted
in coprecipitation of the RT p51 subunit. eEF1A has been im-
plicated as a host cofactor for other RNA viruses (12, 14, 23–25).
However, recently, the plant and yeast homologs of eEF1A and
eEF1G (called eEF1Bγ) were found to be important for RNA
replication of tomato bushy stunt virus (TBSV) through inter-
actions with the viral RNA–dependent RNA polymerase
(RdRp) and RNA stem-loop structures in the viral genome (15).
The RNA binding functions of eEF1A and eEF1Bγ appear to be
essential to stimulate RdRp activity, but whether RNA binding is
relevant to the activity described here remains to be determined.
Although eEF1A and eEF1G can bind cellular and viral RNAs,
they are not known to bind DNA. This could indicate that eEF1
subunits act differently in HIV-1 reverse transcription, where the
stimulatory activity has a greater effect on late rather than early
reverse transcription when the viral genome is mostly or entirely
DNA (9). It is possible that eEF1 subunits may contribute to
early steps of reverse transcription by an RNA-binding mecha-
nism (9).
The observation that down-regulation of eEF1A or eEF1G by
treating cells with siRNA leads to sharply reduced efﬁciency of
reverse transcription, which correlated to signiﬁcantly reduced
levels of RTCs in infected cells, suggests that eEF1 subunits
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HEK293T cell were infected with VSV-G pseudotyped HIV-1pNL4-3.Luc.R-E- or
inactivated HIV-1. Cell lysates were prepared by Dounce homogenization,
clariﬁed by centrifugation, and subjected to isopycnography using a sucrose
gradient. (A) Fractionated gradients were analyzed by quantitative PCR for
viral DNA and (B) by Western blot for HIV-1 RT. (C) Sequential western
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is shown. The results are expressed as phosphorimager (PI) units.
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improve RTC stability in the cytoplasm. One possibility is that
eEF1 or subunits thereof help to maintain the RTC integrity
during the core uncoating process to facilitate late steps of re-
verse transcription (26, 27). Whether eEF1 subunits support
RTC activity directly, protect RTCs from degradation, or both
remains to be determined. Preliminary experiments to recon-
stitute a stimulatory effect in ERT assays with highly puriﬁed
recombinant eEF1A and eEF1G have not succeeded, indicating,
among the many possibilities, that other factors in DAF may
contribute to the stimulatory activity or perhaps posttranslational
modiﬁcations of eEF1 subunits may be required. Determination
of the minimum components required to stimulate late steps of
reverse transcription is an important long-term goal. Of the listed
host factors known to associate with HIV-1 proteins, only a few
directly interact with RT or IN or affect reverse transcription. Six
of the 25 listed proteins (Table S1) have been demonstrated to
interact with components of the HIV-1 RTC or have been im-
plicated in retroviral reverse transcription. Like eEF1A and
eEF1G, some of these are abundant cellular proteins. HSP90AB1,
an isoform of the heat shock 90 protein family, was also identiﬁed
and has been linked to reverse transcription of hepatitis B virus and
the RNA replication of hepatitis C and inﬂuenza viruses (28–30).
Similarly, the ATP-dependent RNA helicase A (DHX9) has been
hypothesized to play a role in HIV-1 reverse transcription (31) by
facilitating tRNA annealing onto the viral genomicRNA (32). Also
detected was XRCC6 (also known as Ku70), a subunit of the ATP-
dependent complex that protects HIV-1 integrase from the host
ubiquitin-proteasome system and, together with PRKDC, asso-
ciates with HIV-1 preintegration complexes (33, 34). Finally, our
mass spectrometry analysis may have missed some important fac-
tors, as proteins smaller than 30 kDa were not included due to poor
protein resolution following SDS/PAGE. For example, DAF con-
tains all subunits of eEF1 complex, including eEF1B2 (25 kDa) and
eEF1D (31 kDa) (Fig. S2), but these were not detected by mass
spectrometry analysis. Experiments to determine whether other
cellular proteins identiﬁed in DAF contribute to the stimulatory
activity are proceeding.
Further analysis of eEF1:RTC interactions could lead to novel
antiviral strategies; indeed, novel ﬂavonoid drugs have recently
been shown to target eEF1A1 (35). However, compounds tar-
geting RT that block interaction with eEF1 may be effective
HIV-1 inhibitors. Many questions remain, such as whether cel-
lular factors in DAF other than eEF1 subunits are required
for stimulating reverse transcription in vitro and in cells, and
determining precisely how eEF1 interacts with RT and IN.
Experiments addressing this possibility are likely to provide keys
to understanding HIV-1 reverse transcription and transport of
the RTC/PIC from the cytoplasm to the nucleus.
Methods
Cell Lines and Viruses. HeLa, HEK293T and Jurkat cells were cultured as pre-
viously described (4). AmphoPhoenix cells were maintained as recommended
by the supplier (ATCC). Stocks of HIVNL4.3 were generated by transfection of
HEK293T cells with proviral DNA using Lipofectamine 2000 (Invitrogen)
according to the manufacturer’s instructions. Stocks of HIV-1pNL4-3.Luc.R-E-
were pseudotyped by cotransfecting proviral plasmid with an expression
plasmid encoding the VSV-G protein. Stocks of MLV-A were made by trans-
fecting AmphoPhoenix cells with the retroviral vector pSAMEN-EGFP (36).
Lysate Preparation and Protein Fractionation by Column Chromatography.
S100 lysate and PGF were prepared from 1011 Jurkat cells as previously de-
scribed (4, 9). Brieﬂy, the S100 lysate was fractionated by gel ﬁltration
through CL-4B size exclusion matrix (Sigma Aldrich) collecting the void vol-
ume protein that is called PGF (9). To obtain DAF, PGF protein of 1 or 10 mg
was fractionated by using a 1-mL or 5-mL HiTrap DEAE FF column (GE
Healthcare), respectively. The bound proteins were eluted from the column
with a NaCl gradient (0–1 M) in S100 buffer in 20 fractions of 1 mL or 5 mL
each, respectively. Each fraction was dialyzed using 3.5-kDa MWCO dialysis
units against S100 dialysis buffer and 0.1 M PMSF. The activities of dialyzed
fractions were tested in ERT assays (4).
ERT Assay. ERT assays were performed using partially puriﬁed HIV-1 as pre-
viously described (4, 9). Brieﬂy, 25 μL of the chromatography fractions or cell
lysate containing speciﬁed amounts of protein were added to 50-μL ERT
reactions as indicated, and 0.2 mM Triton X-100 was the last component
added. A no-DNA control was always included. Standard primer sets used for
ampliﬁcation of strong-stop DNA, and for second-strand transfer DNA were
previously described (9).
Mass Spectrometry. Active chromatography fractions were precipitated with
20% (vol/vol) trichloroacetic acid, resuspended in protein sample buffer, and
separated by SDS/PAGE. Following electrophoresis, gels were stained with
Bio-safe Coomassie stain (Bio-Rad). In-gel tryptic digest was performed on
excised protein bands and extracted peptides were resuspended in 5% (vol/
vol) formic acid. Samples were analyzed by LC-MS/MS on a Nano HPLC
(Shimadzu) coupled to a QStar Elite mass spectrometer (AB SCIEX) with
a nano electrospray source. The data were acquired and processed using
Analyst QS 2.0 software (AB SCIEX). Proteins were identiﬁed by database
searching using Protein Pilot 3.0 (AB SCIEX) against the UniProt_
Sprot_20110325 database (105,198 entries searched). Proteins were consid-
ered identiﬁed if there were two or more peptides identiﬁed with a 99%
conﬁdence and a 1% global false discovery rate.
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Fig. 6. Down-regulation of eEF1A or eEF1G inhibits HIV-1 reverse transcription. HEK293T cells were reverse transfected with siRNA to eEF1G, eEF1A, or
a control siRNA. Untreated, siRNA-treated, or AZT-treated cells were infected with HIV-1 as indicated. (A) Western blots of lysates from siRNA-treated cells
using antibodies as indicated. (B) Reverse transcription efﬁciency for treated cells was compared with untreated cells where the ratio of late to early DNA was
considered as 100%. Early and late DNA levels in total DNA from control and siRNA-treated cells as indicated normalized to the cellular β-globin gene levels in
each sample. (C) Analysis of fractionated gradients as previously described (Fig. 4) for reverse transcriptase by Western blot analysis (Fig. S8) and early HIV-1
DNA by qPCR. All qPCR reactions were performed in triplicate and the mean value and SDs are shown. Digital exposures of Western blots were analyzed using
ImageQuant 5.1. The experiment was repeated three times, with similar results, and a representative data set is shown.
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Immunodepletion, Coimmunoprecipitation, and Western Blot Analysis. The
immunodepletion and coimmunoprecipitation experiments used large-scale
ERT reactions (×10). Antibodies to translation factors (1–10 μg) or BSA (10 μg)
were cross-linked to beads (Pierce). For each immunodepletion, 500 μL di-
alyzed DAF was incubated with antibody or BSA-linked beads for 2 h at 4 °C
and unbound fractions were collected. The unbound fractions and un-
treated DAF were precipitated as previously described before separation by
SDS/PAGE. Western blots were probed with relevant primary antibodies
α-eEF1A (Santa Cruz), α-eEF1G (Abcam), or α-eIF3A (CST) followed by ap-
propriate HRP-conjugated secondary antibodies and detection by chem-
iluminescence. Unbound fractions were also tested in large-scale ERT
reactions. The immunoprecipitated proteins were assayed by Western blot
using human α-HIV, rabbit α-RT, or mouse α-IN mAb (Diatheva) and detected
by chemiluminescence.
RTC Puriﬁcation and Western Blot Analysis. Puriﬁcation of HIV RTC was carried
out as previously described (19), with minor modiﬁcations, using HEK293T
and HIV-1pNL4-3.Luc.R-E- (or heat-inactivated virus, 65 °C, 20 min) containing
1 μg CAp24 at 4 °C for 2 h with polybrene (80 μg/mL) and then incubated at
37 °C for 4 h. The cell lysate were placed on top of a linear sucrose gradient
(20–70%, wt/wt) and subjected to centrifugation at 145,000 × g for 18 h at
4 °C. Twelve fractions were collected from the tube bottom and assayed by
qPCR for HIV-1 strong stop DNA as previously described (9) using 0.2 μL of
each fraction. Protein was extracted from each fraction using chloroform
and methanol in the presence of 1 μg BSA. The recovered protein was
subjected to SDS/PAGE and Western blot analysis, as indicated.
PLA. HeLa cells were incubated with VSV-G pseudotyped HIV-1pNL4-3.Luc.R-E-
(2 h, 4 °C) to allow virus attachment. Cells were then incubated (4 h, 37 °C) to
permit virus fusion and at least partial core uncoating and reverse tran-
scription. Duolink proximity ligation assays (Olink) were performed accord-
ing to the manufacturer’s instructions using infected and uninfected HeLa
cells with a mouse monoclonal antibody to detect HIV-1 RT in conjunction
with rabbit antibodies to eEF1A (Santa Cruz), eEF1G (Sigma), or eIF3A (CST).
DAPI stain was used to visualize the nuclei. Both infected and uninfected
cells were visualized using a DeltaVision Core imaging system. Maximum-
intensity projections of deconvolved images were analyzed using Duolink
Image Tool software. Equal numbers of cells were analyzed from at least
three ﬁelds containing >10 cells.
siRNA Experiments. siRNA (Sigma-Aldrich) targeting eEF1A (siRNA ID:
SASI_Hs02_00331773) and eEF1G (siRNA ID: SASI_Hs02_00331781) or negative
control siRNA (SIC001) were applied to HEK293T cells by large-scale reverse
transfection using Lipofectamine RNAiMAX according to the manufacturer’s
instructions (Invitrogen). The treated and control cells were seeded onto 10-
cm dishes, six dishes per treatment, and incubated at 37 °C for 48 h. The
transfected cells were infected in duplicate with VSV-G pseudotyped HIV-
1pNL4-3.Luc.R-E- (200 ng CAp24) or with inactivated virus at 4 °C for 2 h with
addition of polybrene (80 μg/mL) and then incubated at 37 °C for 5 h.
Separate plates were used for the following: (i) Western blot assays as de-
scribed, and cell viability measured using CellTiter 96Aqueous MTS reagent
(Promega) (one plate); (ii) DNA extraction (QIAamp DNA Mini kit; Qiagen)
for TaqMan qPCR of HIV-1 early and late DNA products as previously de-
scribed (one plate); and (iii) RTC analysis as previously described (four plates).
Untreated cells were incubated with AZT (Sigma-Aldrich) at 30 μM and in-
cubated overnight before infection. Forward and reverse oligonucleotide
primers used for PCR of HIV-1 samples and cycling conditions were as pre-
viously described (9). The TaqMan probe used for HIV-1 quantitative PCR was
5′(6FAM)CAGAGAGCTCCCAGGCTCAGATC(TAM). Oligonucleotides for MLV
qPCR are described elsewhere (Fig. S8).
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Fig. S1. Analysis of cellular factors that are important for reverse transcription. (A) Jurkat cell lysate enhances in vitro HIV-1 reverse transcription in a titratable
manner. Increasing amounts of Jurkat S100 lysate were added to ERT reactions in triplicate as shown. Early (◆) and late (□) reverse transcription products were
quantiﬁed by qPCR. The means and standard deviations of DNA copies detected are shown. The experiment was repeated three times with similar results, and
a representative data set is shown. (B) SDS/PAGE analysis of Jurkat cell lysate and protein fractions. S100 lysate, the “peak of gel ﬁltration” (PGF), and “DEAE
active fraction” (DAF) were separated by SDS/PAGE, and protein bands were stained with Coomassie. Approximately 25 slices of separated DAF protein bands
were processed for mass spectrometry analysis. A representative puriﬁcation and mass spectrometry analysis of four experiments is shown (Table S1).
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Fig. S2. Analysis of eEF1 complex proteins in DAF. (A) The eEF1 complex according to Mansilla et al. (1). (B) Western blot analysis of PGF and DAF for eEF1D
and eEF1B2 as indicated. (C) PGF was incubated with agarose beads linked with an α-eEF1G monoclonal antibody (lane 3) or control beads (lane 2). PGF (lane 1)
and the unbound fractions were assayed by Western blot using rabbit antibodies against eEF1G, eEF1A, eEF1B2, and eEF1D, as indicated. The experiment was
performed twice, with similar results.
1. Mansilla F, et al. (2002) Mapping the human translation elongation factor eEF1H complex using the yeast two-hybrid system. Biochem J 365:669–676.
Fig. S3. Up-scale puriﬁcation of DAF and analysis. Partially puriﬁed active fraction (10 mg, PGF) was further puriﬁed by anion exchange chromatography. A
5-mL HiTrap DEAE FastFlow column (GE Healthcare) was equilibrated with column buffer (25 mL of 10 mM Tris, pH 8.0, 10 mM KCl, 1.5 mM MgCl2) before
sample loading. The column was washed with column buffer (25 mL) and eluted with 100 mL column buffer in a linear NaCl (0–1 M) gradient collected in 5-mL
fractions. Before use in subsequent assays, fractions were dialyzed three times for 30 min against 3 L dialysis buffer (10 mM Tris, pH 8.0, 10 mM KCl, 1.5 mM
MgCl2, 0.5 mM β-mercaptoethanol, and 0.1 mM PMSF). The total protein concentration of collected fractions was determined by the Bradford method against
a Jurkat S100 lysate standard. SDS/PAGE and Western blot analysis was performed with 20 μg protein from each fraction using antibodies as indicated. ERT
assays were performed in triplicate as described previously (1) using 1 μg total protein from each fraction. The level of HIV-1 reverse transcription DNA products
was determined as previously described. The mean fold increase in reverse transcription efﬁciency and the SD is indicated. Minus sign designates that reverse
transcription stimulatory activity was not detected. *P < 0.05 by Welch’s two-tailed t test comparing experimental and control samples. FT, ﬂow through
fraction.
1. Warrilow D, et al. (2008) Cell factors stimulate human immunodeﬁciency virus type 1 reverse transcription in vitro. J Virol 82:1425–1437.
Fig. S4. The eEF1 complex proteins are present in soluble and insoluble protein lysates. S100 and P100 fractions prepared as described (4) were analyzed by
SDS/PAGE and Western blot analysis using 10 μg of total protein from each fraction and antibodies as indicated.
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Fig. S5. HIV-1 RTCs from infected cells cosediment with eEF1A and eEF1G. HEK293T cell were infected with VSV-G pseudotyped HIV-1pNL4-3.Luc.R-E- or with the
same virus that was heat-inactivated. The ﬁrst lane of each Western blot is recombinant RT. Sequential Western blot analysis of the same blot was performed
using (A) a rabbit anti-RT polyclonal antibody, (B) a mouse monoclonal antibody to eEF1G, (C) and then a rabbit polyclonal antibody to eEF1A. The experiment
was repeated three times, and a representative result is shown.
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Fig. S6. Duolink PLA. (A) PLA was performed using a mouse monoclonal antibody to RT in conjunction with rabbit antibodies to eEF1A, eEF1G, or eIF3A
individually with HIV-1–infected or uninfected cells, as indicated (Fig. 5). PLA can determine whether two proteins are within a distance of 40 nm. (B) Species-
speciﬁc secondary antibodies conjugated to PLA+ or PLA− oligonucleotide probes were able to hybridize using linker DNA forming nonligated, circular DNA.
(C) Following a DNA ligation step, synthetic DNA was ampliﬁed by rolling circle polymerization and (D) detected by hybridization of “red” oligonucleotide
probes complementary to the synthetic DNA. (E) The hybridized probe is visible as “red” foci by ﬂuorescent microscopy. HIV-1 RT is associated with eEF1A and
eEF1G in infected cells. HeLa cells were infected with VSV-G pseudotyped HIV-1pNL4-3.Luc.R-E- at 4 °C for 2 h to allow virus attachment to cells, followed by
incubation at 37 °C for 4 h to permit virus fusion and at least partial capsid uncoating and reverse transcription. (F and G) PLA were performed using a mouse
monoclonal antibody to RT in conjunction with rabbit antibodies to eEF1A, eEF1G, or eIF3A individually with HIV-1–infected or uninfected cells as indicated.
DAPI stain was used to visualize nuclei. Maximum-intensity projections of deconvolved images were analyzed using Duolink Image Tool software. Equal
numbers of cells (n = 34) were analyzed from at least three ﬁelds containing >10 cells. The experiment was repeated three times, and a representative result is
shown. (H) Uninfected HeLa cells were stained with the same antibodies to each translation factor, detected by a FITC-labeled anti-rabbit antibody, and vi-
sualized using a Deltavision Core.
Warren et al. www.pnas.org/cgi/content/short/1204673109 4 of 7
Fig. S7. Cell viability of HEK293T cells following treatment with siRNAs. HEK293T cells were treated with siRNAs as described in Methods. Cell viability was
determined using the CellTiter 96 Aqueous One Solution assay according to the manufacturer’s recommendations. The average cell viability, compared with an
untreated control, for two independent experiments and the SDs are shown.
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Fig. S8. Analysis of reverse transcription in knock-down cells by eEF1A or eEF1G siRNAs. (A) Down-regulation of eEF1A and eEF1G does not inhibit MLV-A
reverse transcription. Cells were treated with siRNA as described. MLV-A virus-like particle (VLP) stocks were produced by transfection of pSAMEN-EGFP into
AmphoPhoenix HEK293T cells. All virus stocks were treated with DNaseI. Virus titer was determined by limiting dilution as previously described (1). HEK293T
cells were treated with siRNA as indicated (Fig. 6), and treated and untreated cells were infected with 4 × 105 transduction units of MLV-A-EGFP VLP. In
addition, cells were treated with AZT (30 μM) before infection, or untreated cells were exposed to heat-inactivated virus (70 °C, 30 min). The infections
proceeded for 4 h, and total DNA was collected from cell lysates as in Fig. 6. The level of viral DNA was measured using the oligonucleotides; U5 reverse, 5′
AATGAAAGACCCCCGAGCCG; UTR reverse, 5′TGGTCCCTGGGCGGGGGTCT and U5 forward, 5′AAGCCTCTTGCTGTTTGCATC. The MLV TaqMan probe used was 5′
(6FAM) GCCTCGCTGTTCCTTGGGAG(TAM) using cycling conditions as described elsewhere (2). All results were normalized to cellular β-globin gene levels in the
DNA samples. The experiment was performed three times, with similar results, and a representative data set is shown. (B) Down-regulation of eEF1A or eEF1G
results in reduced RTCs levels in infected cells. Untreated or siRNA treated HEK293T cells were infected with VSV-G pseudotyped HIV-1pNL4-3.Luc.R-E- as previously
described (Fig. 4). Cell lysates prepared from the infected cells were analyzed by isopycnography. The gradients were fractionated, and the density of each
fraction is shown. Proteins in fractionated gradients were assayed by Western blot using an anti-rabbit antibody to RT. The ﬁrst lane on each blot was re-
combinant RT. Arrows designate RTp51. The experiment was performed twice, with similar results. A representative data set is shown.
1. Fassati A (2009) Methods of preparation and analysis of intracellular reverse transcription complexes. Methods Mol Biol 485:107–119.
2. Warrilow D, et al. (2008) Cell factors stimulate human immunodeﬁciency virus type 1 reverse transcription in vitro. J Virol 82:1425–1437.
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Table S1. Proteins present in highly puriﬁed active fractions as identiﬁed by mass spectrometry
Host protein Gene symbol* No. times identiﬁed† Predicted molecular weight (kDa) No. peptides‡
Translation factors
Eukaryotic translation elongation factor 1-α1 EEF1A1 4 50 10
Eukaryotic translation elongation factor 1-γ EEF1G 3 50 6
Eukaryotic translation elongation factor 2 EEF2 3 95 16
Eukaryotic translation initiation factor 3 subunit A EIF3A 4 167 10
Transcription regulators
ATP-dependent DNA helicase 2 subunit 1 XRCC6 4 70 13
ATP-dependent RNA helicase A DHX9 3 141 10
DNA-dependent protein kinase, catalytic subunit PRKDC 3 469 5
Interleukin enhancer binding protein factor 2 ILF2 3 43 3
Synthetases
Glutamyl-prolyl tRNA synthetase EPRS 3 171 4
Isoleucyl-tRNA synthetase IARS 3 144 11
Methionyl-tRNA synthetase MARS 4 101 6
mRNA splicing and transport factors
Heterogeneous nuclear ribonucleoprotein K HNRNPK 3 51 3
Heterogeneous nuclear ribonucleoprotein U HNRNPU 3 91 9
Nucleoprotein TPR TPR 3 267 12
Splicing factor 3A subunit 3 SF3A3 3 59 4
Folding and transport proteins
Clathrin heavy chain 1 CLTC 3 192 7
Heat shock 70kDa protein 8 HSPA8 4 70 34
Heat shock protein HSP90B HSP90AB1 3 83 25
T-complex protein 1 subunit theta CCT8 3 60 8
Cellular organization and cytoskeleton proteins
Actin γ1 ACTG1 3 41 8
Filamin A FLNA 3 281 29
Filamin B FLNB 3 278 49
Myosin IIA, heavy chain 9, nonmuscle MYH9 4 227 22
Spectrin α SPTAN1 4 285 35
Spectrin β SPTBN1 3 275 51
Proteins present in highly puriﬁed active fractions (DAF) were identiﬁed by mass spectrometry. Proteins were considered “identiﬁed” if two or more
peptides with >95% conﬁdence were detected. Twenty-ﬁve proteins were consistently detected in four independent puriﬁcations and are listed above,
grouped by their protein functions.
*Ofﬁcial gene symbol listed by UniProt.
†Number of active fractions protein was detected in (out of 4 independent puriﬁcations).
‡Average number of peptides from the protein sequence detected by mass spectrometry with >95% conﬁdence.
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